Heartseed has granted Novo the exclusive rights to develop, manufacture, and sell HS-001, regenerated cardiomyocytes derived from heterologous iPS cells in the world except Japan. In Japan, Heartseed will continue to develop the product independently, while retaining the rights to develop, manufacture and market it. After obtaining approval, Heartseed will market the product jointly with Novo’s Japanese subsidiary. License fees may add up to up to 65.5 billion yen (500 million €). In the second half of 2021, HeartSeed plans to start a domestic Phase 1/2 clinical trial (LAPiS trial) for severe heart failure caused by ischemic heart disease as a corporate trial.

Nikkei Biotech news release, July 14, 2021